The therapeutic potential of new investigational hepatitis C virus translation inhibitors

References

• Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362.
   PubMed Web of Science ®Google Scholar
• Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol. 2006;25:71–99.
   Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):S45–S57.
   PubMed Web of Science ®Google Scholar
• Thomas DL. Global control of hepatitis C: where challenges meets opportunity. Nat Med. 2013;19:850–858.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.
   PubMed Web of Science ®Google Scholar
• Gentile I, Maraolo AE, Buonomo AR, et al. The discovery of sofosbuvir: a devolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363–1377.
   PubMed Web of Science ®Google Scholar
• McCornachie SM, Wilhelm SM, Kale-Pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev Clin Pharmac. 2016;9:287–302.
   PubMed Web of Science ®Google Scholar
• Scheel TKH, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19:837–849.
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.
   PubMed Web of Science ®Google Scholar
• Andrieux-Meyer I, Cohn J, Affonso de Araújo ESA, et al. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health. 2015;11:e676–e677.
   Google Scholar
• Suzuki T, Ishii K, Aizaki H, et al. Hepatitis C viral life cycle. Adv Drug Deliv Rev. 2007;59:1200–1212.
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Crouchet E, Baumert TF, et al. Host-targeting agents to prevent and cure hepatitis C virus infection. Viruses. 2015;7:5659–5685.
   PubMed Web of Science ®Google Scholar
• Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol. 2013;369:167–198.
   PubMed Web of Science ®Google Scholar
• Dubuisson G, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle – an update. J Hepatol. 2014;61(Suppl 1):S3–S13.
   PubMed Web of Science ®Google Scholar
• Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013;369:113–142.
   PubMed Web of Science ®Google Scholar
• Balvay L, Soto RR, Ricci EP, et al. Structural and functional diversity of viral IRESes. Biochim Biophys Acta. 2009;1789:542–557.
   PubMed Web of Science ®Google Scholar
• Hoffman B, Liu Q. Hepatitis C viral protein translation: mechanisms and implications in developing antivirals. Liver Int. 2011;31:1449–1467.
   PubMed Web of Science ®Google Scholar
• Pérard J, Leyrat C, Baudin F, et al. Structure of the full-length HCV-IRES in solution. Nat Commun. 2013;4:1612.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hanecak R, Brown-Driver V, et al. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother. 1999;43:347–353.
   PubMed Web of Science ®Google Scholar
• McCaffrey AP, Meuse L, Karimi M, et al. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology. 2003;38:503–508.
   PubMed Web of Science ®Google Scholar
• Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci USA. 2003;100:235–240.
   PubMed Web of Science ®Google Scholar
• Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003;4:602–608.
   PubMed Web of Science ®Google Scholar
• Kanda T, Steele R, Ray R, et al. Small interfering RNA targeted to hepatitis C virus 5ʹ nontranslated region exerts potent antiviral effect. J Virol. 2007;81:669–676.
   PubMed Web of Science ®Google Scholar
• Romero-López C, Barroso-delJesus A, Puerta-Fernández E, et al. Interfering with hepatitis C virus IRES activity using RNA molecules identified by a novel in vitro selection method. Biol Chem. 2005;386:183–190.
   PubMed Web of Science ®Google Scholar
• Da Rocha Gomes S, Dausse E, Toulmé JJ. Determinants of apical loop-internal loop RNA-RNA interactions involving the HCV IRES. Biochem Biophys Res Commun. 2004;322:820–826.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Umehara T, Fukuda K, et al. A hepatitis C virus (HCV) internal ribosome entry site (IRES) domain III-IV-targeted aptamer inhibits translation by binding to an apical loop of domain IIId. Nucleic Acids Res. 2005;33:683–692.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Umehara T, Nishikawa F, et al. Increased inhibitory ability of conjugated RNA aptamers against the HCV IRES. Biochem Biophys Res Commun. 2009;386:118–123.
   PubMed Web of Science ®Google Scholar
• Romero-López C, Berzal-Herranz B, Gomez J, et al. An engineered inhibitor RNA that efficiently interferes with hepatitis C virus translation and replication. Antiviral Res. 2012;94:131–138.
   PubMed Web of Science ®Google Scholar
• Romero-López C, Díaz-Gonzalez R, Berzal-Herranz A. Inhibition of hepatitis C virus internal ribosome entry site-mediated translation by an RNA targeting the conserved IIIf domain. Cell Mol Life Sci. 2007;64:2994–3006.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther. 2008;16:1481–1489.
   PubMed Web of Science ®Google Scholar
• Romero-López C, Díaz-González R, Barroso-delJesus A, et al. Inhibition of HCV replication and IRES-dependent translation by an RNA molecule. J Gen Virol. 2009;90:1659–1669.
   PubMed Web of Science ®Google Scholar
• Dibrov SM, Parson J, Carnevali M, et al. Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site. J Med Chem. 2014;57:1694–1707.
   PubMed Web of Science ®Google Scholar
• Ottosen S, Parsley TB, Yang L, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015;59:599–608.
   PubMed Web of Science ®Google Scholar
• Gebert LF, Rebhan MA, Crivelli SE, et al. Miravirsen (SPC3649) can inhibit the biogenesis. Nucleic Acids Res. 2014;42:609–621.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Baek J, Kang S, Min H. MicroRNA-targeting therapeutics for hepatitis C. Arch Pharma Res. 2014;37:299–305.
   PubMed Web of Science ®Google Scholar
• Henke JI, Goergen D, Zheng J, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008;27:3300–3310.
   PubMed Web of Science ®Google Scholar
• Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science. 2005;309:1577–1581.
   PubMed Web of Science ®Google Scholar
• Machlin ES, Sarnow P, Sagan SM. Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A. 2011;108:3193–3198.
   PubMed Web of Science ®Google Scholar
• Shimakami T, Yamane D, Jangra RK, et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A. 2012;109:941–946.
   PubMed Web of Science ®Google Scholar
• Li YP, Gottwein JM, Scheel TK, et al. MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR. Proc Natl Acad Sci U S A. 2011;108:4991–4996.
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:89–899.
   Web of Science ®Google Scholar
• Hildebrandt-Eriksen ES, Aarup V, Persson HF, et al. A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther. 2012;22:152–161.
   PubMed Web of Science ®Google Scholar
• Soler M, McHutchison JG, Kwoh TJ, et al. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther. 2004;9:953–968.
   PubMed Web of Science ®Google Scholar
• Hanecak R, Brown-Driver V, Fox MC, et al. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol. 1996;70:5203–5212.
   PubMed Web of Science ®Google Scholar
• Bhat B, Neben S, Tay J, et al. RG-101, a GalNAc-conjugated anti-miR employing a unique mechanism of action by targeting host factor microrNA-122 (miR-122), demonstrates potent activity and reduction of HCV in preclinical studies. 64th Annual Meeting of the American Association for the Study of Liver Diseases: the Liver Meeting 2013; 2013 Nov 1-2; Washington.
   Google Scholar
• Lavender H, Brady K, Burden F, et al. In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy. Antimicrob Agents Chemother. 2012;56:1364–1375.
   PubMed Web of Science ®Google Scholar
• Denise H, Moschos SA, Sidders B, et al. Deep sequencing insights in therapeutic shRNA processing and siRNA target cleavage precision. Molecular Therapy—Nucleic Acids. 2014;3:e145.
   Web of Science ®Google Scholar
• Cholongitas E, Papatheodororids V. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther. 2008;27:866–884.
   PubMed Web of Science ®Google Scholar
• Janseen HL, Reesink WH, Lawitz EJ, et al. Treatment of HCV infection by targeting MicroRNA. NEJM. 2013;368:18.
   Web of Science ®Google Scholar
• McHutchison JG, Patel K, Pockros P, et al. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J Hep. 2006;44:88–96.
   PubMed Web of Science ®Google Scholar
• RG-101 Targeting miR-122 for HCV. [cited 2016 May 18]. Available from: http://www.regulusrx.com/therapeutic-areas/rg-101/
   Google Scholar
• Suhy D, Patel K, Kilfoil G, et al. Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV). Hepatology. 2015;62:1386A.
   Web of Science ®Google Scholar
• Update on TT-034 Hepatitis C clinical trial. [cited 2016 May 18]. Available from: http://www.prnewswire.com/news-releases/update-on-tt-034-hepatitis-c-clinical-trial-300226692.html
   Google Scholar
• Crooke S. Antisense drug technology, principles, strategies and applications. 2nd ed. Boca Raton (FL): CRC Press; 2007.
   Google Scholar
• Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients (NCT NCT00229749). [cited 2016 May 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT00229749
   Google Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther. 2014;12:763–773.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia F, et al. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs. 2014;23:719–728.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia G. Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials. 2014;9:115–123.
   PubMedGoogle Scholar
• Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
   PubMed Web of Science ®Google Scholar
• Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
   PubMed Web of Science ®Google Scholar